Top Midday Decliners
MapLight Therapeutics' (MPLT) shares tumbled 68% even after the company said its phase 2 trial of ML
Keep reading this article with Yahoo Finance Plus Silver
Silver
- Premium news Full access to Financial Times and MT Newswires articles
- Stock picks Expert picks from Motley Fool, Zacks, and Moby
- Research reports Expert analysis from Morningstar and Argus
